drugset
drugset / Trial / NCT07447726

Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

NCT07447726 ↗

Phase 1/2 Not yet recruiting 3 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, single-arm, prospective, exploratory clinical trial involving patients with relapsed/refractory large B-cell lymphoma, aiming to preliminarily assess the safety and efficacy of CAR-T cell infusion.

Timeline

Start
2026-04-05
Primary completion
2028-01-01
Completion
2028-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19X CAR-T Cell therapy 1e+06 cells/kg Other
Subject CD19X CAR-T Cell therapy 2e+06 cells/kg Other

Indications

large B-cell lymphoma